Reported 2 days ago
Pfizer's stock has plummeted over 50% since late 2021, primarily due to the decline in vaccine-related optimism and impending patent expirations for key drugs. Despite significant challenges, including a recent acquisition to bolster its drug pipeline and a positive regulatory agreement with the U.S. government, analysts remain cautious about recommending Pfizer, noting that it is not among the top investment picks. While the stock has seen a recent uptick, potential investors are advised to weigh the risks, especially regarding its high payout ratio and dividend reliability.
Source: YAHOO